// App-Quantinova.ai

279 : Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup.

Researchers

Presenter

  • Kuaile Zhao

Principal Investigators

  • Sung-Bae Kim

  • Ken Kato

  • Chih-Hung Hsu

  • Sheng Hu

  • Feng Wang

  • Takashi Kojima

  • Young Saing Kim

  • Eric Van Cutsem

  • Jaffer A. Ajani

  • Liyun Li

  • Ningning Ding

  • Aiyang Tao

  • Lin Shen

Medical Centers

  • Department of Radiation Oncology, Jiangxi Cancer Hospital, Nanchang, China

  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of (South), Korea

  • Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

  • Hubei Cancer Hospital, Wuhan, China

  • Department of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China

  • Depertment of Surgical Oncology, National Cancer Center Hospital East, Chiba, Japan

  • Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea (the Republic of)

  • Digestive Oncology, University Hospitals Gasthuisberg/Leuven and KULeuven, Leuven, Belgium

  • BeiGene Ltd, Zhongguancun Life Science Park, Beijing, China

  • BeiGene Ltd, Zhongguancun Life Science Park, Beijing, China

  • Department of Thoracic Medical Oncology, Peking University Cancer Hospital & Institute, Beijing, China

Locations

  • China

  • Republic of South Korea

  • Japan

  • Taiwan

  • Belgium

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Esophageal squamous carcinoma cell

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Tislelizumab

  • Irinotecan

  • Paclitaxel

  • Docetaxel

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT03430843

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved